Literature DB >> 26400835

Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.

Petra Jacobs1, Alfonso Ang2, Maureen P Hillhouse2, Andrew J Saxon3, Suzanne Nielsen4, Paul G Wakim5, Barbara E Mai6, Larissa J Mooney2, Jennifer S Potter7, Jack D Blaine1.   

Abstract

BACKGROUND AND OBJECTIVES: Induction is a crucial period of opioid addiction treatment. This study aimed to identify buprenorphine/naloxone (BUP) induction patterns and examine their association with outcomes (opioid use, retention, and related adverse events [AEs]).
METHODS: The secondary analysis of a study of opioid-dependent adults seeking treatment in eight treatment settings included 740 participants inducted on BUP with flexible dosing.
RESULTS: Latent class analysis models detected six distinctive induction trajectories: bup1-started and remained on low; bup2-started low, shifted slowly to moderate; bup3-started low, shifted quickly to moderate; bup4-started high, shifted to low; bup5-started and remained on moderate; bup6-started moderate, shifted to high dose (Fig. 1). Baseline characteristics, including Clinical Opioid Withdrawal Scale (COWS), were important predictors of retention. When controlled for the baseline characteristics, bup6 participants were three times less likely to drop out the first 7 days than bup1 participants (adjusted hazard ratio (aHR) = .28, p = .03). Opioid use and AEs were similar across trajectories. Participants on ≥16 mg BUP compared to those on <16 mg at Day 28 were less likely to drop out (aHR = .013, p = .001) and less likely to have AEs during the first 28 days (aOR = .57, p = .03). DISCUSSION AND
CONCLUSIONS: BUP induction dosing was guided by an objective measure of opioid withdrawal. Participants with higher baseline COWS whose BUP doses were raised more quickly were less likely to drop out in the first 7 days than those whose doses were raised slower. SCIENTIFIC SIGNIFICANCE: This study supports the use of an objective measure of opioid withdrawal (COWS) during BUP induction to improve retention early in treatment. © American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26400835      PMCID: PMC5322942          DOI: 10.1111/ajad.12288

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  20 in total

1.  Severity of dependence and route of administration of heroin, cocaine and amphetamines.

Authors:  M Gossop; P Griffiths; B Powis; J Strang
Journal:  Br J Addict       Date:  1992-11

Review 2.  Effect of buprenorphine dose on treatment outcome.

Authors:  Ayman Fareed; Sreedevi Vayalapalli; Jennifer Casarella; Karen Drexler
Journal:  J Addict Dis       Date:  2012

Review 3.  Update on the clinical use of buprenorphine: in opioid-related disorders.

Authors:  Simon Ducharme; Ronald Fraser; Kathryn Gill
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

4.  The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.

Authors:  Suzanne Nielsen; Maureen Hillhouse; Roger D Weiss; Larissa Mooney; Jennifer Sharpe Potter; Joshua Lee; Marc N Gourevitch; Walter Ling
Journal:  Am J Addict       Date:  2013-09-24

Review 5.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2014-02-06

6.  Psychiatric comorbidity and additional abuse of drugs in maintenance treatment with L- and D,L-methadone.

Authors:  Dirk Wedekind; Stefan Jacobs; Iris Karg; Christel Luedecke; Udo Schneider; Konrad Cimander; Pierre Baumann; Eckart Ruether; Wolfgang Poser; Ursula Havemann-Reinecke
Journal:  World J Biol Psychiatry       Date:  2010-03       Impact factor: 4.132

7.  Factors associated with complicated buprenorphine inductions.

Authors:  Susan D Whitley; Nancy L Sohler; Hillary V Kunins; Angela Giovanniello; Xuan Li; Galit Sacajiu; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2010-07

8.  Prognostic factors in Buprenorphine- versus methadone-maintained patients.

Authors:  R S Schottenfeld; J R Pakes; T R Kosten
Journal:  J Nerv Ment Dis       Date:  1998-01       Impact factor: 2.254

9.  Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study.

Authors:  Michael Soyka; Christina Zingg; Gabriele Koller; Heinrich Kuefner
Journal:  Int J Neuropsychopharmacol       Date:  2008-01-21       Impact factor: 5.176

Review 10.  Pharmacologic treatments for opioid dependence: detoxification and maintenance options.

Authors:  Herbert D Kleber
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

View more
  5 in total

1.  What methods are used to study the association between medication adherence trajectories, estimated with the group-based trajectory modeling (GBTM) method, and health-related outcomes?-a protocol for a systematic review.

Authors:  Victoria Memoli; Giraud Ekanmian; Sophie Lauzier; Line Guénette; Carlotta Lunghi; Anne-Déborah Bouhnik
Journal:  Syst Rev       Date:  2022-05-23

2.  Longitudinal trajectories of antidepressant use in pregnancy and the postnatal period.

Authors:  Gretchen Bandoli; Grace M Kuo; Renu Sugathan; Christina D Chambers; Matthieu Rolland; Kristin Palmsten
Journal:  Arch Womens Ment Health       Date:  2018-01-16       Impact factor: 3.633

3.  US physicians' decision-making during buprenorphine-naloxone treatment: Conjoint analyses of dose and office visit adjustments based on patient progress.

Authors:  Hannah K Knudsen; Michelle R Lofwall; Lewei Allison Lin; Sharon L Walsh; Jamie L Studts
Journal:  Drug Alcohol Depend       Date:  2019-08-30       Impact factor: 4.852

Review 4.  Treatment of opioid dependence with buprenorphine: current update.

Authors:  Michael Soyka
Journal:  Dialogues Clin Neurosci       Date:  2017-09       Impact factor: 5.986

5.  High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder.

Authors:  Andrew A Herring; Aidan A Vosooghi; Joshua Luftig; Erik S Anderson; Xiwen Zhao; James Dziura; Kathryn F Hawk; Ryan P McCormack; Andrew Saxon; Gail D'Onofrio
Journal:  JAMA Netw Open       Date:  2021-07-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.